Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Transfusion ; 53(11 Suppl 2): 2850-8, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24111785

RESUMO

BACKGROUND: Genotyping for red blood cell (RBC), platelet (PLT), and granulocyte antigens is a new tool for clinical pathology, transfusion medicine services, and blood banks. Proficiency in laboratory tests can be established by external quality assessments (EQAs), which are required for clinical application in many health care systems. There are few EQAs for molecular immunohematology. STUDY DESIGN AND METHODS: We analyzed the participation and pass rates in an EQA for RBC, PLT, and granulocyte antigens. This EQA was distributed by INSTAND, a large nonprofit provider of proficiency tests, twice per year since Fall 2006 as EQA Number 235 Immunohematology A (molecular diagnostic). The coordinators defined at the outset which alleles are mandatory for detection. RESULTS: The number of participants steadily increased from 51 to 73 per proficiency by Fall 2012. More than 60 institutions utilized this EQA at least once a year. Approximately 80% of them participated in RBC, 68% in PLT, and 22% in granulocyte systems. With the exceptions of RHD (82%) and granulocytes (85%), pass rates exceeded 93%. While the pass rate increased for granulocyte and decreased for the ABO system, the pass rates for the other systems changed little over 6½ years. CONCLUSIONS: The INSTAND proficiency test program was regularly used for EQA by many institutions, particularly in Central Europe. While the technical standards and pass rates in the participating laboratories were high, there has been little improvement in pass rates since 2006.


Assuntos
Sistema ABO de Grupos Sanguíneos/genética , Tipagem e Reações Cruzadas Sanguíneas , Plaquetas/imunologia , Eritrócitos/imunologia , Granulócitos/imunologia , Ensaio de Proficiência Laboratorial , Sistema ABO de Grupos Sanguíneos/imunologia , Bancos de Sangue/normas , Europa (Continente) , Humanos
2.
Infect Immun ; 77(10): 4631-42, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19620341

RESUMO

We previously described that low-dose Mycobacterium tuberculosis infection in cynomolgus macaques results in a spectrum of disease similar to that of human infection: primary disease, latent infection, and reactivation tuberculosis (S. V. Capuano III, D. A. Croix, S. Pawar, A. Zinovik, A. Myers, P. L. Lin, S. Bissel, C. Fuhrman, E. Klein, and J. L. Flynn, Infect. Immun. 71:5831-5844, 2003). This is the only established model of latent infection, and it provides a unique opportunity to understand host and pathogen differences across of range of disease states. Here, we provide a more extensive and detailed characterization of the gross pathology, microscopic histopathology, and immunologic characteristics of monkeys in each clinical disease category. The data underscore the similarities between human and nonhuman primate M. tuberculosis infection. Furthermore, we describe novel methods of quantifying gross pathology and bacterial burden that distinguish between active disease and latent infection, and we extend the usefulness of this model for comparative studies. Early in infection, an abnormal chest X ray, M. tuberculosis growth by gastric aspirate, and increased mycobacterium-specific gamma interferon (IFN-gamma) in peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage (BAL) cells were associated with the development of active disease. At necropsy, disease was quantified with respect to pathology and bacterial numbers. Microscopically, a spectrum of granuloma types are seen and differ with disease type. At necropsy, monkeys with active disease had more lung T cells and more IFN-gamma from PBMC, BAL, and mediastinal lymph nodes than monkeys with latent infection. Finally, we have observed a spectrum of disease not only in monkeys with active disease but also in those with latent infection that provides insight into human latent tuberculosis.


Assuntos
Mycobacterium tuberculosis/imunologia , Tuberculose/imunologia , Tuberculose/patologia , Animais , Sangue/imunologia , Líquido da Lavagem Broncoalveolar/imunologia , Contagem de Colônia Microbiana , Modelos Animais de Doenças , Granuloma/patologia , Interferon gama/metabolismo , Leucócitos Mononucleares/imunologia , Pulmão/microbiologia , Pulmão/patologia , Linfonodos/microbiologia , Linfonodos/patologia , Macaca fascicularis , Radiografia Torácica , Índice de Gravidade de Doença , Estômago/microbiologia
4.
Ann Clin Lab Sci ; 43(1): 91-3, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23462612

RESUMO

The hereditary or acquired deficiency of ADAMTS-13 activity leads to an excess of high molecular weight von Willebrand factor multimers in plasma, leading to platelet aggregation and diffuse intravascular thrombus formation, resulting in thrombotic thrombocytopenic purpura (TTP). We report a 36 year old male with a long history of TTP associated with 33 relapses. As a result of early transfusions, the patient acquired Hepatitis C. This time, the patient presented with a TTP relapse after a 10 year remission, following PEG-interferon-Alpha (IFA) therapy for Hepatitis C. Since IFA has been reported to activate autoimmune reactions, it may have augmented production of ADAMTS-13 antibody.


Assuntos
Púrpura Trombocitopênica Trombótica/patologia , Proteínas ADAM/metabolismo , Proteína ADAMTS13 , Adulto , Humanos , Masculino , Púrpura Trombocitopênica Trombótica/tratamento farmacológico , Púrpura Trombocitopênica Trombótica/enzimologia , Recidiva
5.
Arthritis Rheum ; 62(2): 340-50, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20112395

RESUMO

OBJECTIVE: An increased risk of tuberculosis has been documented in humans treated with tumor necrosis factor alpha (TNFalpha)-neutralizing agents. In murine models, impaired signaling by TNF causes exacerbation of both acute and chronic infection associated with aberrant granuloma formation and maintenance. This study was undertaken to investigate immune modulation in the setting of TNF neutralization in primary and latent tuberculosis in a non-human primate model. METHODS: Cynomolgus macaques 4 years of age or older were infected with Mycobacterium tuberculosis and subjected to clinical, microbiologic, immunologic, and radiographic examinations. Monkeys were classified as having active or latent disease 6-8 months after infection, based on clinical criteria. Monkeys used in acute infection studies were randomized to receive either adalimumab (prior to and during infection) or no treatment. Monkeys with latent infection that were randomized to receive TNF-neutralizing agent were given either an inhibitor of soluble TNF, recombinant methionyl human soluble TNF receptor I (p55-TNFRI), or adalimumab. Control monkeys with latent infection were given no treatment or saline. Data from previously studied monkeys with active or latent disease were also used for comparison. RESULTS: Administration of TNF-neutralizing agents prior to M tuberculosis infection resulted in fulminant and disseminated disease by 8 weeks after infection. Neutralization of TNF in latently infected cynomolgus macaques caused reactivation in a majority of animals as determined by gross pathologic examination and bacterial burden. A spectrum of dissemination was noted, including extrapulmonary disease. Surprisingly, monkeys that developed primary and reactivation tuberculosis after TNF neutralization had similar granuloma structure and composition to that of control monkeys with active disease. TNF neutralization was associated with increased levels of interleukin-12, decreased levels of CCL4, increased chemokine receptor expression, and reduced mycobacteria-induced interferon-gamma production in blood but not in the affected mediastinal lymph nodes. Finally, the first signs of reactivation often occurred in thoracic lymph nodes. CONCLUSION: These findings have important clinical implications for determining the mechanism of TNF neutralization-related tuberculosis.


Assuntos
Anticorpos Monoclonais/farmacologia , Antirreumáticos/farmacologia , Mycobacterium tuberculosis/imunologia , Tuberculose dos Linfonodos/imunologia , Tuberculose Pulmonar/imunologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Doença Aguda , Adalimumab , Animais , Anticorpos Monoclonais Humanizados , Quimiocina CCL4/imunologia , Quimiocina CCL4/metabolismo , Doença Crônica , Modelos Animais de Doenças , Granuloma/imunologia , Granuloma/microbiologia , Granuloma/patologia , Terapia de Imunossupressão/efeitos adversos , Interferon gama/imunologia , Interferon gama/metabolismo , Interleucina-12/imunologia , Interleucina-12/metabolismo , Interleucina-2/imunologia , Interleucina-2/metabolismo , Interleucina-8/imunologia , Interleucina-8/metabolismo , Macaca fascicularis , Tuberculose dos Linfonodos/patologia , Tuberculose Pulmonar/patologia , Fator de Necrose Tumoral alfa/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA